QURE on Nasdaq
uniQure N.V.
Pharmaceutical preparations company, listed on Nasdaq (QURE).
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with KIORA PHARMACEUTICALS INC, Zhengye Biotechnology Holding Ltd or VERU INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-1151.4%Operating margin3
-1236.0%Net margin3
-40.6%Revenue growth, 20253
-100.0%Return on equity3
0.25×Debt to equity3
-$178.4MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License brought in 99% of the revenue uniQure N.V. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| License | $2.8M | $10.1M | $15.9M |
| Collaboration revenues | $2.2M | $10.9M | $164.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$1.7M
- Research and development66¢$140.7M
- Selling, general and admin31¢$65.5M
- Income tax3¢$5.6M
Out of $16.1M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $16.1M | $27.1M | $15.8M |
| Cost of license revenues | -$1.7M | -$1.3M | -$65.0K |
| Cost of contract manufacturing revenues | -$17.1M | -$13.6M | |
| Research and development expenses | -$140.7M | -$143.8M | -$214.9M |
| Selling, general and administrative expenses | -$65.5M | -$52.7M | -$74.6M |
| Total operating expenses | -$207.8M | -$214.8M | -$303.1M |
| Other income | $14.4M | $7.9M | $6.1M |
| Other expense | -$8.0M | -$4.6M | -$1.7M |
| Loss from operations | -$185.3M | -$184.3M | -$282.9M |
| Interest income | $17.0M | $21.4M | $19.6M |
| Interest expense | -$62.0M | -$63.7M | -$41.6M |
| Foreign currency gains / (losses), net | $26.1M | -$10.5M | -$1.7M |
| Other non-operating gains, net | $10.9M | ||
| Loss before income tax expense | -$193.3M | -$237.1M | -$306.6M |
| Income tax expense | -$5.6M | -$2.4M | -$1.9M |
| Net loss | -$199.0M | -$239.6M | -$308.5M |
| Foreign currency translation (losses) / gains, net | -$6.2M | $426.0K | $6.9M |
| Defined benefit pension gain / (loss), net of taxes | $771.0K | $327.0K | -$2.1M |
| Total comprehensive loss | -$204.4M | -$238.8M | -$303.7M |
| Basic net loss per ordinary share | -$3.46 | -$4.92 | -$6.47 |
| Diluted net loss per ordinary share | -$3.46 | -$4.92 | -$6.47 |
| Weighted average shares - basic | 57.5M shares | 48.6M shares | 47.7M shares |
| Weighted average shares - diluted | 57.5M shares | 48.6M shares | 47.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $80.2M | $158.9M | $241.4M | |
| Current investment securities | $542.3M | $208.6M | ||
| Accounts receivable | $5.9M | $5.9M | ||
| Prepaid expenses | $20.5M | $9.3M | ||
| Other current assets and receivables | $7.1M | $7.6M | ||
| Total current assets | $656.0M | $390.3M | ||
| Property, plant and equipment, net | $13.8M | $20.4M | ||
| Other investments | $30.2M | $27.5M | ||
| Operating lease right-of-use assets | $12.5M | $13.6M | ||
| Intangible assets, net | $72.8M | $71.0M | ||
| Goodwill | $25.4M | $22.4M | ||
| Deferred tax assets, net | $8.7M | $9.9M | ||
| Other non-current assets | $5.6M | $1.4M | ||
| Total non-current assets | $168.9M | $166.2M | ||
| Total assets | $824.9M | $556.5M | ||
| Accounts payable | $5.2M | $7.2M | ||
| Accrued expenses and other current liabilities | $41.3M | $29.2M | ||
| Liability related to pre-funded warrants | $12.6M | |||
| Current portion of operating lease liabilities | $3.9M | $3.6M | ||
| Total current liabilities | $62.9M | $40.1M | ||
| Long-term debt | $49.7M | $51.3M | ||
| Liability from royalty financing agreement | $473.2M | $434.9M | ||
| Operating lease liabilities, net of current portion | $9.8M | $11.1M | ||
| Contingent consideration | $18.7M | $10.9M | ||
| Deferred tax liability, net | $8.0M | $7.0M | ||
| Other non-current liabilities, net of current portion | $3.7M | $7.9M | ||
| Total non-current liabilities | $563.1M | $523.2M | ||
| Total liabilities | $626.0M | $563.3M | ||
| Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of December 31, 2025 and December 31, 2024 and 62,336,717 and 48,988,087 ordinary shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $3.7M | $2.9M | ||
| Additional paid-in-capital | $1.6B | $1.2B | ||
| Accumulated other comprehensive loss | -$58.2M | -$52.8M | ||
| Accumulated deficit | -$1.3B | -$1.1B | ||
| Total shareholders' equity / (deficit) | $198.9M | -$6.8M | $207.7M | $476.0M |
| Total liabilities and shareholders' equity / (deficit) | $824.9M | $556.5M | ||
| Ordinary shares, par value (in euros per share) | 0.05 EUR | 0.05 EUR | ||
| Ordinary shares, authorized | 80.0M shares | 80.0M shares | ||
| Ordinary shares, issued | 62.3M shares | 49.0M shares | ||
| Ordinary shares, outstanding | 62.3M shares | 49.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $80.2M | $158.9M | $241.4M | |
| Current investment securities | $542.3M | $208.6M | ||
| Accounts receivable | $5.9M | $5.9M | ||
| Prepaid expenses | $20.5M | $9.3M | ||
| Other current assets and receivables | $7.1M | $7.6M | ||
| Total current assets | $656.0M | $390.3M | ||
| Property, plant and equipment, net | $13.8M | $20.4M | ||
| Other investments | $30.2M | $27.5M | ||
| Operating lease right-of-use assets | $12.5M | $13.6M | ||
| Intangible assets, net | $72.8M | $71.0M | ||
| Goodwill | $25.4M | $22.4M | ||
| Deferred tax assets, net | $8.7M | $9.9M | ||
| Other non-current assets | $5.6M | $1.4M | ||
| Total non-current assets | $168.9M | $166.2M | ||
| Total assets | $824.9M | $556.5M | ||
| Accounts payable | $5.2M | $7.2M | ||
| Accrued expenses and other current liabilities | $41.3M | $29.2M | ||
| Liability related to pre-funded warrants | $12.6M | |||
| Current portion of operating lease liabilities | $3.9M | $3.6M | ||
| Total current liabilities | $62.9M | $40.1M | ||
| Long-term debt | $49.7M | $51.3M | ||
| Liability from royalty financing agreement | $473.2M | $434.9M | ||
| Operating lease liabilities, net of current portion | $9.8M | $11.1M | ||
| Contingent consideration | $18.7M | $10.9M | ||
| Deferred tax liability, net | $8.0M | $7.0M | ||
| Other non-current liabilities, net of current portion | $3.7M | $7.9M | ||
| Total non-current liabilities | $563.1M | $523.2M | ||
| Total liabilities | $626.0M | $563.3M | ||
| Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of December 31, 2025 and December 31, 2024 and 62,336,717 and 48,988,087 ordinary shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $3.7M | $2.9M | ||
| Additional paid-in-capital | $1.6B | $1.2B | ||
| Accumulated other comprehensive loss | -$58.2M | -$52.8M | ||
| Accumulated deficit | -$1.3B | -$1.1B | ||
| Total shareholders' equity / (deficit) | $198.9M | -$6.8M | $207.7M | $476.0M |
| Total liabilities and shareholders' equity / (deficit) | $824.9M | $556.5M | ||
| Ordinary shares, par value (in euros per share) | 0.05 EUR | 0.05 EUR | ||
| Ordinary shares, authorized | 80.0M shares | 80.0M shares | ||
| Ordinary shares, issued | 62.3M shares | 49.0M shares | ||
| Ordinary shares, outstanding | 62.3M shares | 49.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$199.0M | -$239.6M | -$308.5M |
| Depreciation and amortization | $14.8M | $12.6M | $11.9M |
| Amortization of discount on investment securities | -$10.5M | -$10.9M | -$10.9M |
| Share-based compensation expense | $17.7M | $22.3M | $35.1M |
| Royalty financing agreement interest expense, net of interest paid | $38.8M | $44.2M | $25.6M |
| Deferred tax expense | $1.6M | $2.4M | $1.9M |
| Changes in fair value of contingent consideration | $6.2M | -$1.8M | $15.9M |
| Changes in fair value of liability related to pre-funded warrants | -$12.4M | ||
| Unrealized foreign exchange (gains) / losses, net | -$23.0M | $15.4M | -$2.2M |
| Other items, net | -$5.4M | -$3.8M | $4.7M |
| Accounts receivable, prepaid expenses, and other current assets and receivables | -$8.6M | -$2.2M | -$1.3M |
| Accounts payable | -$2.7M | $1.5M | -$4.2M |
| Accrued expenses, other liabilities, and operating leases | $4.5M | -$5.6M | -$5.3M |
| Contingent consideration milestone payments | -$19.6M | -$1.9M | |
| Inventories | $2.4M | -$6.7M | |
| Contract asset related to CSL Behring milestone payments | $100.0M | ||
| Net cash used in operating activities | -$178.0M | -$182.7M | -$145.9M |
| Proceeds on maturity of debt securities | $337.2M | $534.5M | $167.9M |
| Investment in debt securities | -$658.4M | -$359.8M | -$366.4M |
| Divestment of commercial manufacturing facility | -$8.3M | ||
| Purchases of property, plant, and equipment | -$439.0K | -$3.4M | -$7.2M |
| Net cash (used in) / generated from investing activities | -$321.6M | $163.0M | -$205.7M |
| Proceeds from follow-on public offerings of ordinary shares, net of issuance costs | $380.7M | ||
| Proceeds from issuance of pre-funded warrants, net of issuance costs | $23.5M | ||
| Proceeds from issuance of ordinary shares related to employee stock options and purchase plans | $11.2M | $2.1M | $308.0K |
| Repayment of long-term debt | -$53.0M | ||
| Contingent consideration milestone payments | -$8.6M | -$7.6M | |
| Proceeds from royalty financing agreement, net of issuance costs | $370.1M | ||
| Net cash generated from / (used in) financing activities | $415.4M | -$59.5M | $362.7M |
| Currency effect on cash, cash equivalents and restricted cash | $5.7M | -$5.0M | $2.3M |
| Net (decrease) / increase in cash, cash equivalents and restricted cash | -$78.5M | -$84.2M | $13.4M |
| Cash paid for interest | -$25.1M | -$20.6M | -$16.9M |
| Non-cash decrease in accounts payables and accrued expenses and other current liabilities related to purchases of property, plant, and equipment | -$99.0K | -$672.0K | -$513.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led uniQure N.V., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
20202025
- Chief executive officerMatthew C. Kapusta Jan 5, 2017 to now12
- PresidentRicardo Dolmetsch Sep 17, 2020 to Sep 20, 202313
- Chief financial officerChristian Klemt Jun 17, 2021 to now14
- Chief financial officerMatthew C. Kapusta Jan 5, 2017 to Jan 28, 202212
- Chief operating officerPierre Caloz Jun 17, 2021 to Jun 20, 202415
- Chief operating officerScott T. McMillan Aug 16, 2017 to Jan 30, 201916
Board members and other officers (26)
- Chief Customer & Strat OfficerKylie O'Keefe Mar 9, 2026 to now17
- OfficerJeannette Potts Jun 15, 2023 to Jun 15, 202318
- Chief Medical OfficerWalid Abi-Saab Oct 2, 2023 to now19
- SVP, Investor Relations & CommMaria E. Cantor Jan 3, 2018 to Jan 30, 201820
- Chief Medical OfficerRobert Gut Sep 25, 2018 to Jan 28, 202121
- Chief Business OfficerJonathan Garen Jan 5, 2017 to Jan 30, 201822
- Chief Medical OfficerChristian Meyer Jan 6, 2017 to Feb 21, 201723
- Chief Scientific OfficerHarald Petry Jan 6, 2017 to Jun 29, 201724
- Chief Commercial OfficerPaul E. Firuta Jan 9, 2017 to Jan 30, 201825
- Sr VP of Regulatory AffairsAlexander Edward Kuta Iii. Feb 1, 2017 to Mar 9, 202326
- Chief Medical OfficerSteven Zelenkofske Jun 7, 2017 to Jun 8, 201827
- Chief Accounting OfficerChristian Klemt Aug 8, 2017 to Mar 4, 202128
- Chief Scientific OfficerDeventer Sander Van Sep 22, 2017 to Mar 2, 202029
- Board memberRachelle Suzanne Jacques Oct 22, 2021 to now30
- Board memberLeonard E. Post Jun 23, 2020 to now31
- Board memberRobert Gut Jun 18, 2018 to now32
- Board memberDavid Schaffer Jan 3, 2017 to Mar 2, 202033
- Board memberDeventer Sander Van Jan 3, 2017 to Jan 31, 201734
- Board memberPaula Soteropoulos Jan 3, 2017 to Jun 17, 202435
- Board memberPhilip Astley-Sparke Jan 4, 2017 to Mar 4, 202136
- Board memberMatthew C. Kapusta Jan 5, 2017 to now12
- Board memberJack Kaye Jan 10, 2017 to now37
- Board memberMadhavan Balachandran Sep 22, 2017 to now38
- Board memberJeremy P. Springhorn Sep 26, 2017 to now39
- General counselJeannette Potts Mar 5, 2024 to now40
- General counselMaiken Keson-Brookes Jan 5, 2017 to Feb 21, 201741
Former names
- uniQure B.V.Nov 8, 2013 to Feb 6, 20142
Timeline
- Jan 5, 2017New chief executive Matthew C. Kapusta becomes CEO12
Filings
413 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 71 major events, 192 insider forms, 54 large holders, 76 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Sep 2, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Jul 29, 2026S-8 EDGAR
- Jul 29, 202610-Q EDGAR
- Jul 29, 20268-K EDGAR
- Jul 20, 2026SCHEDULE 13G/A EDGAR
- Jul 16, 2026SCHEDULE 13G EDGAR
- Jul 7, 20264 PRIMARY DOCUMENT EDGAR
- Jul 2, 2026144 EDGAR
- Jul 2, 20264 PRIMARY DOCUMENT EDGAR
- Jul 2, 20264 PRIMARY DOCUMENT EDGAR
- Jun 30, 2026144 EDGAR
- Jun 30, 2026144 EDGAR
- Jun 30, 20264 PRIMARY DOCUMENT EDGAR
- Jun 26, 2026144 EDGAR
- Jun 26, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 2026144 EDGAR
- Jun 24, 2026144 EDGAR
The 413 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 54 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Jul 20, 2026SCHEDULE 13G/A
- Jul 16, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 12, 2026SCHEDULE 13G
- May 6, 2026SCHEDULE 13G/A
- Apr 30, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARuniQure N.V. filings on SEC EDGAR
- 2SEC EDGARuniQure N.V. filings on SEC EDGAR
- 3SEC EDGARuniQure N.V. 10-K for fiscal 2025
- 4SEC EDGARuniQure N.V. 10-K for fiscal 2019
- 5SEC EDGARuniQure N.V. 10-K for fiscal 2020
- 6SEC EDGARuniQure N.V. 10-K for fiscal 2021
- 7SEC EDGARuniQure N.V. 10-K for fiscal 2022
- 8SEC EDGARuniQure N.V. 10-Q for fiscal 2025
- 9SEC EDGARuniQure N.V. 10-Q for fiscal 2025
- 10SEC EDGARuniQure N.V. 10-Q for fiscal 2026
- 11SEC EDGARuniQure N.V. 10-K for fiscal 2019
- 12
- 13SEC EDGARRicardo Dolmetsch, President
- 14
- 15
- 16
- 17
- 18SEC EDGARJeannette Potts, Officer
- 19
- 20
- 21SEC EDGARRobert Gut, Chief Medical Officer
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31SEC EDGARLeonard E. Post, Board member
- 32SEC EDGARRobert Gut, Board member
- 33SEC EDGARDavid Schaffer, Board member
- 34SEC EDGARDeventer Sander Van, Board member
- 35SEC EDGARPaula Soteropoulos, Board member
- 36SEC EDGARPhilip Astley-Sparke, Board member
- 37SEC EDGARJack Kaye, Board member
- 38SEC EDGARMadhavan Balachandran, Board member
- 39SEC EDGARJeremy P. Springhorn, Board member
- 40SEC EDGARJeannette Potts, General counsel
- 41